December 5, 2020 05:05 PM ESTUpdated December 7, 07:29 AM
R&D

#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

Nicole DeFeudis

Editor

Af­ter kick­ing off a mul­ti­ple myelo­ma ri­val­ry with Bris­tol My­ers Squibb at last year’s ASH, Re­gen­eron is back with an up­dat­ed safe­ty and dura­bil­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times